Yttrium-90
Updates to Article Attributes
Yttrium-90 (90Y) is a radioisotope; derived from the decay of 90Sr.
Yttrium-90 decays due to the emission of β- particles, with a half-life of 2.67 days 5. It canhas no gamma energy emission, but may be used for metabolic radiopharmaceuticalimaged through the use of bremsstrahlung interactions with planar or SPECT imaging. A small amount of internal pair production also enables the use of PET imaging. These unique features enable both diagnostic imaging and therapy, for example: non-Hodgkin B-cell lymphomamaking it a popular theranostic agent.
Clinical use
The radioimmunotherapy (radiopharmaceutical therapy and immunotherapy). The radiopharmaceutical used is 90Y-ibritumomab tiuxetan; it is a murine monoclonal antibody (mAb) directed at human CD20. Radioactive yttrium is bound to the mAb through the tiuxetan, a bifunctional chelator. It is approved for the treatment of non-Hodgkin B-cell lymphoma.
Radiosynoviorthesis (RSO) is the intra-articular injection of beta-particle emitting radiocolloids. Colloidal yttrium-90 citrate is the radiopharmaceutical used in radiosynoviorthesis (RSO), the radionuclide therapyRSO for the treatment of joint inflammation 4.
Transarterial radioembolisation utilises Yttrium-90 microspheres in the treatment of unresectable hepatic malignancy, which includes hepatocellular cancer, neuroendocrine and colorectal liver metastases.
Chemical-physical characteristics
Yttrium belongs to the group of transition metals; it has atomic number (Z) 39 and atomic weight 88.90585
Its electronic configuration is: [Kr] 4d1 5s2
The maximum energy of the emitted particles is 2.28 MeV with an average path in the human tissuses of approximately 5.8 mm. It decays into the non-radioactive isotope 90Zr.
History and etymology
Yttrium was discovered in 1794 by Johan Gadolin, a Finnish chemist, in a sample of mineral originating from Ytterby (Sweden).
-<p><strong>Yttrium-90 (<sup>90</sup>Y)</strong> is a radioisotope; derived from the decay of <sup>90</sup>Sr.</p><p>Yttrium-90 decays due to the emission of β- particles, with a half-life of 2.67 days <sup>5</sup>. It can be used for metabolic radiopharmaceutical therapy, for example: non-Hodgkin B-cell lymphoma radioimmunotherapy (radiopharmaceutical therapy and immunotherapy). The radiopharmaceutical used is <sup>90</sup>Y-ibritumomab tiuxetan; it is a murine monoclonal antibody (mAb) directed at human CD20. Radioactive yttrium is bound to the mAb through the tiuxetan, a bifunctional chelator.</p><h5>Radiosynoviorthesis </h5><p>Colloidal yttrium-90 citrate is the radiopharmaceutical used in radiosynoviorthesis (RSO), the radionuclide therapy for the treatment of joint inflammation <sup>4</sup>.</p><h5>Chemical-physical characteristics</h5><p>Yttrium belongs to the group of transition metals; it has atomic number (Z) 39 and atomic weight 88.90585</p><p>Its electronic configuration is: [Kr] 4d1 5s2</p><p>The maximum energy of the emitted particles is 2.28 MeV with an average path in the human tissuses of approximately 5.8 mm. It decays in the non-radioactive isotope <sup>90</sup>Zr.</p><h4>History and etymology</h4><p>Yttrium was discovered in 1794 by Johan Gadolin, a Finnish chemist, in a sample of mineral originating from Ytterby (Sweden).</p>- +<p><strong>Yttrium-90 (<sup>90</sup>Y)</strong> is a radioisotope derived from the decay of <sup>90</sup>Sr.</p><p>Yttrium-90 decays due to the emission of β- particles, with a half-life of 2.67 days <sup>5</sup>. It has no gamma energy emission, but may be imaged through the use of <a href="/articles/bremsstrahlung-radiation" title="Bremsstrahlung radiation">bremsstrahlung </a>interactions with planar or SPECT imaging. A small amount of internal <a href="/articles/pair-production" title="Pair production">pair production</a> also enables the use of PET imaging. These unique features enable both diagnostic imaging and therapy, making it a popular <a href="/articles/theranostics" title="Theranostics">theranostic </a>agent. </p><h4>Clinical use</h4><p>The radioimmunotherapy <a href="/articles/yttrium-90-ibritumomab-tiuxetan" title="Yttrium-90 ibritumomab tiuxetan"><sup>90</sup>Y-ibritumomab tiuxetan</a> is a murine monoclonal antibody (mAb) directed at human CD20. Radioactive yttrium is bound to the mAb through the tiuxetan, a bifunctional chelator. It is approved for the treatment of non-Hodgkin B-cell lymphoma. </p><p>Radiosynoviorthesis (RSO) is the intra-articular injection of beta-particle emitting radiocolloids. Colloidal yttrium-90 citrate is the radiopharmaceutical used in RSO for the treatment of joint inflammation <sup>4</sup>.</p><p><a href="/articles/selective-internal-radiation-therapy" title="Transarterial radioembolization">Transarterial radioembolisation</a> utilises Yttrium-90 microspheres in the treatment of unresectable hepatic malignancy, which includes <a href="/articles/hepatocellular-cancer">hepatocellular cancer</a>, <a href="/articles/neuroendocrine-tumours">neuroendocrine</a> and <a href="/articles/colorectal-cancer-1">colorectal</a> liver metastases. </p><h4>Chemical-physical characteristics</h4><p>Yttrium belongs to the group of transition metals; it has atomic number (Z) 39 and atomic weight 88.90585</p><p>Its electronic configuration is: [Kr] 4d1 5s2</p><p>The maximum energy of the emitted particles is 2.28 MeV with an average path in the human tissuses of approximately 5.8 mm. It decays to the non-radioactive isotope <sup>90</sup>Zr.</p><h4>History and etymology</h4><p>Yttrium was discovered in 1794 by Johan Gadolin, a Finnish chemist, in a sample of mineral originating from Ytterby (Sweden).</p>
Tags changed:
- theranostics
Unable to process the form. Check for errors and try again.